US-authorized BESREMi® Now Available

FORUS Therapeutics is pleased to announce that US-authorized BESREMi® (ropeginterferon alfa-2b-njft), is now available in Canada, via Exceptional Importation.

Please note, BESREMi®’s active ingredient, ropeginterferon alfa-2b-njft, has not been reviewed under Health Canada’s standard drug review process and is not found in any other drug previously authorized for sale in Canada.

Please refer to the below for important information:

Materials for Healthcare Professionals

• Risk Communication Letter
• Availability Notice
• US-authorized BESREMi® Prescribing Information

Materials for Patients

• Medication Guide
• Instructions for Use
• Instructions for Use (printer friendly)
• Dosage Reminder

BESREMi® Packaging Images

• Carton Contents
• Carton Label
• BESREMi® Single Use Pre-Filled Syringe with Needle Attached
• BESREMi® Syringe Label

Note: The Ontario PIN for BESREMi® is 09858357.

At FORUS, we are committed to patient safety. To report a side effect/adverse reaction or for medical questions or product quality complaints, please contact us:

Phone: 1-866-542-7500

Monday to Friday, 9 a.m. – 5 p.m. (EST), excluding holidays

BESREMi® is a registered trademark of PharmaEssentia Corporation used under license by FORUS Therapeutics Inc. All rights reserved.